Biotech Values

[biomaven0]

There are always going to be challenges to a patent if the drug is successful. But pretty close to zero chance that someone can just copy their drug before the patent expires - this is a complex large molecule.

So all that is likely at issue is whether others might find freedom to operate in the same space. If others desperately want to do so, that would be very good news. Perhaps analogous to the patent fight over PD1 - there BMY and ONO claim that Merck and others are infringing and they are due a royalty.